4. TG Therapeutics Inc. (NASDAQ: TGTX)
TG Therapeutics, Inc. (NASDAQ: TGTX) ranks fourth among the best cheap biotech stocks to buy now following strong revenue growth driven by its flagship therapy BRIUMVI. The company focuses on developing treatments for autoimmune diseases and B-cell malignancies.
Financial results released on February 26 revealed total revenue of $192.6 million in the fourth quarter and $616.3 million for the full year of 2025. Much of that growth was fueled by BRIUMVI, which generated $182.7 million in U.S. revenue during the quarter and nearly $594 million for the full year.
BRIUMVI’s rapid adoption reflects growing physician confidence in the therapy’s effectiveness in treating multiple sclerosis. The company is also expanding internationally through its partnership with Neuraxpharm, which has helped secure regulatory approvals across multiple regions including the European Union, the United Kingdom, Switzerland, and Australia.
Management expects total global revenue to reach between $875 million and $900 million in 2026, signaling continued commercial momentum.
Click next to see the following stock...
